

- insulin resistance in healthy volunteers: results from the STRIBILD-IR study. *Antivir Ther* [ePub ahead of print].
- Stek A, Best BM, Wang J et al. (2015). Pharmacokinetics of once versus twice daily darunavir in pregnant HIV-infected women. *J Acquir Immune Defic Syndr* **70**: 33.
- Stellbrink HJ, leFevre E, Carr A et al. (2016). Once daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment. *AIDS* **30**: 1229.
- Surleraux DL, Tahri A, Verschueren WG et al. (2005). Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. *J Med Chem* **48**: 1813.
- Taiwo B, Zheng L, Gallien S et al. (2011). Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naïve HIV-1-infected patients (ACTG A5262). *AIDS* **25**: 2113.
- Tashima K, Crofoot G, Tomaka FL et al. (2014). Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a phase IIIb, open-label single-arm trial. *AIDS Res Ther* **11**: 39.
- Taylor S, Jayasuriya AN, Berry A et al. (2010). Darunavir concentrations exceed the protein-corrected EC₅₀ for wild-type HIV in the semen of HIV-1-infected men. *AIDS* **24**: 2583.
- Tie Y, Boross PI, Wang YF et al. (2004). High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. *J Mol Biol* **338**: 341.
- Violari A, Bologna R, Kumarasamy N et al. (2015). Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients: week 48 results of the ARIEL trial. *Pediatr Infect Dis J* **34**: e132.
- Yazdanpanah Y, Fagard C, Descamps D et al. (2009). High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. *Clin Infect Dis* **49**: 1441.
- Yilmaz A, Izadkhashti A, Price RW et al. (2009). Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. *AIDS Res Hum Retroviruses* **25**: 457.
- Yoshimura K, Kato R, Kavlick MF et al. (2002). A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. *J Virol* **76**: 1349.
- Zorrilla CD, Wright R, Osiyemi OO et al. (2014). Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily. *HIV Med* **15**: 50.